You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

IBD: Preventive Care: Corticosteroid Related Iatrogenic Injury-Bone Loss Assessment

Percentage of patients aged 18 years and older with an inflammatory bowel disease encounter who were prescribed prednisone equivalents greater than or equal to 10 mg/day for 60 or greater consecutive days or a single prescription equating to 600mg prednisone or greater for all fills and were documented for risk of bone loss once during the reporting year or the previous calendar year.

Date Reviewed: November 19, 2017

Measure Info

MIPS 271CMS 271CQMC Core Measure
Measure Type: 
Measure Steward: 
American Gastroenterological Association
Clinical Topic Area: 
Inflammatory Bowel Disease

Care Setting: 
Data Source: 

ACP does not support QPP measure 271: "Preventive Care: Corticosteroid Related Iatrogenic Injury--Bone Loss Assessment." While the measure represents an important clinical concept, measure developers do not cite high-quality evidence to form the basis of the measure and using dexa-scans to assess for risk of bone loss does not necessarily prevent hip fractures in patients prescribed corticosteroid therapy for IBD. Furthermore, implementation could promote overuse of dexa scans and underuse of corticosteroid therapy. The American College of Rheumatology recommends low dose bisphosphonate prophylaxis for patients receiving long-term corticosteroid treatment and alendronate is recommended for patients receiving more than 5 mg of prednisone/day for more than three months. Furthermore, numerator specifications encourage clinicians to screen patients who receive 10 mg/day of prednisone for 60 days, while evidence demonstrates that hip fractures are significantly higher in patients treated with medium steroid doses (2.5-7mg/day) over a duration of time. As written, the numerator could miss patients who are at risk for fracture. Also, it is unclear whether the measure encourages clinicians to screen patients who are currently prescribed prophylactic bisphosphonate therapy for risk of bone loss, which may not be clinically necessary. Lastly, developers should consider revising the numerator specifications to include an evidence-based look-back window for review of medication history. It is burdensome for clinicians to review indefinite data fields for documentation of review of systems and medication history.